LixiLan

- 

What is LixiLan?

LixiLan is an injectable drug which contains a fixed ratio combination of insulin glargine and lixisenatide, a glucagon-like peptide 1 (GLP-1) receptor agonist for the treatment of Type 2 Diabetes. It's given in the form of an injection similar to the modern delivery system of insulin (i.e. in the form of a pen). The drug is injected once a day, subcutaneously, preferably over the abdomen.

How it works

It is a single, once-daily injection to lower both fasting and postprandial blood glucose. Insulin glargine taken generally once a day serves as a basal or ‘background’ insulin. It stays in the body for 18 to 24 hours and is said to have little-to-no peak, providing steady blood sugar management throughout an 18 to 24 hour period.

Lixisenatide is a once-daily GLP-1 receptor agonist. A GLP-1 drug is a peptide that naturally occurs in the human body, released within minutes after eating a meal. It works to lower blood sugar levels by suppressing the natural glucagon secretion from the pancreatic alpha cells. It also stimulates insulin secretion by pancreatic beta cells.